BTIG Research Reaffirms “Buy” Rating for Mobia Medical (NASDAQ:MOBI)

Mobia Medical (NASDAQ:MOBI)‘s stock had its “buy” rating restated by BTIG Research in a research report issued on Tuesday, Benzinga reports. They currently have a $19.00 price target on the stock. BTIG Research’s price target points to a potential upside of 108.33% from the company’s current price.

Several other research analysts have also recently commented on the stock. Weiss Ratings started coverage on shares of Mobia Medical in a research report on Wednesday, August 12th. They issued a “sell (e-)” rating for the company. JPMorgan Chase & Co. boosted their price objective on Mobia Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.75.

Mobia Medical Trading Up 3.5%

NASDAQ MOBI traded up $0.31 during mid-day trading on Tuesday, reaching $9.12. 39,806 shares of the company’s stock traded hands, compared to its average volume of 173,270. The company has a current ratio of 13.28, a quick ratio of 12.80 and a debt-to-equity ratio of 0.04. Mobia Medical has a 1-year low of $8.03 and a 1-year high of $15.29. The firm’s fifty day simple moving average is $10.21. The stock has a market capitalization of $303.60 million and a P/E ratio of -0.45.

Mobia Medical (NASDAQ:MOBI) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.27). The company had revenue of $13.51 million during the quarter. The business’s quarterly revenue was up 102.4% on a year-over-year basis. Equities research analysts forecast that Mobia Medical will post -2.63 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Casey Tansey bought 16,441 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was purchased at an average cost of $12.07 per share, for a total transaction of $198,442.87. Following the completion of the transaction, the director directly owned 318,332 shares of the company’s stock, valued at approximately $3,842,267.24. This trade represents a 5.45% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders purchased a total of 87,000 shares of company stock worth $1,016,367 over the last quarter.

Hedge Funds Weigh In On Mobia Medical

Several hedge funds have recently modified their holdings of MOBI. Readystate Asset Management LP bought a new position in Mobia Medical during the second quarter valued at about $134,000. Citadel Advisors LLC acquired a new stake in Mobia Medical in the 2nd quarter valued at about $670,000. Finally, State Street Corp acquired a new stake in Mobia Medical in the 2nd quarter valued at about $735,000.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.